BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SALVAT Seeks FDA Approval For Its CETRAXAL Otic (Ciprofloxacin Otic) 0.2% Solution, For The Treatment Of External Otitis


10/19/2005 5:13:04 PM

BARCELONA, Spain, April 18 /PRNewswire/ -- SALVAT announce plans to file their CETRAXAL Otic solution, with its convenient, single-dispensing container (SDC) format, with the FDA.

The efficacy and safety of the treatment has been assessed in a 630 patient clinical trial, which will be the basis for their application in the 2nd quarter of 2005.

"We combined the advantages of a proven, effective antibiotic with a simple, accurate form of administration. The idea behind our product is to reduce unnecessary ingredients thus avoiding unexpected adverse reactions, especially problematic in the paediatric population. We are convinced that finding the right commercial partner in the US will help us to bring the benefits of this new product to a great number of patients." said Jordi Julve, COO of SALVAT.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D.

Meet us: 17th PAS-Meeting (Washington 14-17 May)

SALVAT

CONTACT: Dietmar Jannaschk, e-mail: djk@salvat-lab.es, +34-933-946-434



Read at BioSpace.com

   
Otitis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES